La Jolla Pharmaceutical, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, completed the acquisition of Tetraphase Pharmaceuticals, a biopharmaceutical company, for $43m and $16m potentially payable. “Combining with La Jolla, which markets GIAPREZA, the first new treatment for patients suffering from septic or other distributive shock in more than a decade, should help accelerate XERAVA’s availability to patients in need. We are excited to have the opportunity to combine with a company that has a strategic vision similar to our own,” Larry Edwards, Tetraphase President and Chief Executive Officer.